iRadimedFRA:46K +1.81%87 ROA % is 20.99% as of Mar. 2026, which is 31% above its 10-year median of 15.98. GuruFocus rates FRA:46K with a GF Score™ of 87/100 and a GF Value™ of €56.02 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 854 Medical Devices & Instruments companies, iRadimed ranks better than 97.54% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. iRadimed's annualizedNet Income for the quarter that ended in Mar. 2026 was €20.13 Mil.
iRadimed's average Total Assets over the quarter that ended in Mar. 2026 was €95.92 Mil. Therefore, iRadimed's annualized ROA % for the quarter that ended in Mar. 2026 was 20.99%.
The historical rank and industry rank for iRadimed's ROA % or its related term are showing as below:
FRA:46K'
s ROA % Range Over the Past 10 Years
Min: 1.31 Med: 15.98 Max: 21.71
Current: 21.62
During the past 13 years, iRadimed's highest ROA % was 21.71%. The lowest was 1.31%. And the median was 15.98%.
FRA:46K's ROA % is ranked better than 97.54% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.555
vs FRA:46K: 21.62
iRadimed (FRA:46K) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
iRadimed ROA % Related Terms
iRadimed ROA % Historical Data
* Premium members only.
The historical data trend for iRadimed's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, iRadimed's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRadimed ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's ROA % distribution charts can be found below:
* The bar in red indicates where iRadimed's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
iRadimed (FRA:46K) has a ROA % of 20.99% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on iRadimed and its competitors. This is 31% above median its historical median of 15.98. Over the past decade, iRadimed's ROA % has ranged from 1.31 to 21.71. According to the industry distribution chart, iRadimed ranks #21 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 2.5%.
Is iRadimed's ROA % too high?
iRadimed's current ROA % of 20.99% is 31% above median its 10-year median of 15.98. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 21.71. The Medical Devices & Instruments industry median ROA % is 0.56. iRadimed's value of 20.99% is 3682% above this industry median. Based on the distribution chart, iRadimed ranks #21 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, iRadimed has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's ROA % compare to AVNS and LMRI?
According to the Medical Devices & Instruments industry distribution chart, iRadimed ranks #21 out of 854 companies for ROA %. This places iRadimed in the top 3% of its industry — outperforming the majority of peers. The industry median ROA % is 0.56. iRadimed's value of 20.99% is 3682% above this benchmark. Historically, iRadimed's own ROA % has ranged from 1.31 to 21.71 over the past decade. While the company's 10-year median is 15.98 vs. the industry median of 0.56, iRadimed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.56, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRadimed's current ROA % of 20.99% is 3682% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on iRadimed and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRadimed's current ROA % is 20.99%, which is 31% above median its own 10-year median of 15.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (FRA:46K) is currently considered Significantly Overvalued. The stock's GF Value™ is €56.02, compared to a current price of €84.50 — trading 50.8% above its estimated fair value. The current ROA % is 20.99%, which is 31% above median its 10-year median of 15.98 and 3682% above the Medical Devices & Instruments industry median of 0.56. iRadimed's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For iRadimed (FRA:46K), the current ROA % is 20.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRadimed (FRA:46K) Overvalued in 2026?
Based on GuruFocus' analysis, iRadimed stock appears to be overvalued.
The current stock price of €84.50 is trading 50.8% above its estimated GF Value™ of €56.02.
GuruFocus considers iRadimed to be Significantly Overvalued.
Key valuation signals for FRA:46K:
ROA %: 20.99% (31% above median its 10-year median of 15.98)
GF Value™: €56.02 vs. price of €84.50 (50.8% above fair value)
Industry Position: 3682% above the Medical Devices & Instruments median (#21 of 854)
No single metric tells the full story. See the FRA:46K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
87GF Score
Get the complete analysis for FRA:46K
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:46K has been successfully added to your 
